So a few things2 Oct 2015 09:47
Firstly, great news, certainly put my mind (more) at rest, although I'll save the cork-popping till the financing is contractually signed (although I fully expect it to be given quotes from both parties).
Secondly, there is dilution in 2 forms. (1) the convertible will create 93mn new shares which is 33% of the current outstanding issuance. (2) existing shareholders will be effectively diluted by the revenue sharing agreement with Acrux. Whilst the revenue share percentages looks low, remember that it will be a much higher proportion of attributable earnings (ie they get their share of the revenue, but exiting SHs still have to cover all the costs). That said, it's good to see that the revenue share figures fall over time (though remains at 4% on Lemphane for perpetuity it seems).
Finally do we really think they have negotiated a $2mn discount on Mothae? You could read that statement as being that they have to pay them $2m on signing the finance followed by the balance of $6.5m over time. It doesn't seem very clear to me.
So, a good deal, and the stock looks very good value below 5p to me. However, risks still remain until the diamonds start flowing, and we have had to give something away to get the required financing (which is to be expected).